Company profile
Splisense company profile
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.
Business identity
- Website
- https://splisense.com
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Founded
- 2016-01-01, Year
Headquarters
- Headquarters
- Sumbul, North Sumatra, Indonesia
- Postal code
- 9270400
- Country code
- ID
- Continent
- Asia